Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Novan Inc (NOVN) USD0.0001

Sell:$2.17 Buy:$2.22 Change: $0.01 (0.45%)
NASDAQ:0.26%
Market closed |  Prices as at close on 12 November 2019 | Switch to live prices |
Sell:$2.17
Buy:$2.22
Change: $0.01 (0.45%)
Market closed |  Prices as at close on 12 November 2019 | Switch to live prices |
Sell:$2.17
Buy:$2.22
Change: $0.01 (0.45%)
Market closed |  Prices as at close on 12 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Novan, Inc. is a clinical development-stage biotechnology company. The Company is focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases. The Company has created a Nitricil technology platform enabling the development of new chemical entities (NCEs) with delivery of nitric oxide. The Company’s two key components of its nitric oxide platform are its Nitricil technology, which drives the creation of NCEs, and its formulation science, both of which it uses to tune its product candidates for specific indications. Novan’s Nitricil technology enables it to store large amounts of nitric oxide gas in a stable, solid form by chemically loading it on a macromolecule, or polymer. The nitric oxide platform has produced a portfolio that includes the various clinical stage dermatology product candidates: SB204, SB206, SB208 and SB414.

Contact details

Address:
4105 Hopson Rd
MORRISVILLE
27560-9018
United States
Telephone:
+1 (919) 4858080
Website:
www.novan.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NOVN
ISIN:
US66988N1063
Market cap:
$57.35 million
Shares in issue:
26.07 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Robert Ingram
    Independent Chairman of the Board
  • Paula Stafford
    President, Chief Operating Officer
  • G Kelly Martin
    Interim Chief Executive Officer, Director
  • John Gay
    Principal Financial Officer, Secretary
  • Carri Geer
    Senior Vice President and Chief Technology Officer
  • Stanley Hollenbach
    Senior Vice President - Research and Development
  • Andrew Novak
    Vice President, Chief Accounting Officer and Principal Accounting Officer
  • Michelle Patterson
    Vice President of Project Management
  • Brian Johnson
    Chief Commercial Officer
  • Elizabeth Messersmith
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.